Changmao Biochemical Engineering Company Limited provided earnings guidance for the year 2022. The board of directors of the Company announced the shareholders of the Company and potential investors that having assessed the currently available information, the Group is likely to record a consolidated net profit attributable to the equity holders of the Company 2022 of an amount ranging between RMB 70 million to RMB 90 million as compared to consolidated net loss attributable to the equity holders of the Company of RMB 49.2 million for 2021, before taking into account the Demolition Gain.